Industry Category
Business Keywords
Company Description
Endocyte is a leading biopharmaceutical company focused on developing innovative targeted therapies for personalized cancer treatment. Endocyte's proprietary drug conjugation technology precisely targets therapeutics and companion imaging agents to diseased cells, enhancing treatment efficacy and minimizing side effects.
Located at Purdue Research Park, 3000 Kent Avenue, West Lafayette, IN 47906, US, and with an additional location at 8910 Purdue Road, Indianapolis, IN 46268, US, Endocyte is committed to advancing its pipeline of cutting-edge therapies. The company's lead program, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, is entering phase 3 clinical trials for metastatic castration-resistant prostate cancer (mCRPC). Endocyte is also pioneering adaptor-controlled CAR T-cell therapy, currently being studied in osteosarcoma.
Endocyte is dedicated to transforming cancer care through precision medicine. We invite the management team at Endocyte to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work and attract new partners and investors.
Endocyte est une société biopharmaceutique de premier plan axée sur le développement de thérapies ciblées innovantes pour le traitement personnalisé du cancer. La technologie exclusive de conjugaison de médicaments d'Endocyte cible avec précision les agents thérapeutiques et d'imagerie compagnons vers les cellules malades, améliorant ainsi l'efficacité du traitement et minimisant les effets secondaires.
Située au Purdue Research Park, 3000 Kent Avenue, West Lafayette, IN 47906, États-Unis, et avec un emplacement supplémentaire au 8910 Purdue Road, Indianapolis, IN 46268, États-Unis, Endocyte s'engage à faire progresser son pipeline de thérapies de pointe. Le programme phare de la société, une thérapie radioligand ciblant l'antigène membranaire spécifique de la prostate (PSMA), 177Lu-PSMA-617, entre en phase 3 des essais cliniques pour le cancer de la prostate métastatique résistant à la castration (mCRPC). Endocyte est également pionnier dans la thérapie CAR-T contrôlée par adaptateur, actuellement étudiée dans l'ostéosarcome.
Endocyte se consacre à la transformation des soins contre le cancer grâce à la médecine de précision. Nous invitons l'équipe de direction d'Endocyte à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin de mettre davantage en évidence leur travail révolutionnaire et d'attirer de nouveaux partenaires et investisseurs.
Key Personnel / Employees
Compare Companies Side by Side
Compare Endocyte with 1 companies in Pharmaceutical-Manufacturing
| Comparison Field |
EndocyteMain Company |
xcellbioView Profile |
|---|---|---|
|
Founded Year
|
— | |
|
Company Size
|
— | 11-50 |
|
City
|
West Lafayette, IN | San Francisco, California |
|
Country
|
United States | United States |
|
Skills & Keywords
Comparing with main company
|
12 Total Skills
Biopharmaceutical
Targeted Therapy
Cancer Treatment
Drug Conjugation
Radioligand Therapy
CAR T-cell Therapy
Precision Medicine
mCRPC
Companion Imaging
Cancer
Targeted drug therapy
CAR-T
|
22 Total
22 Unique
Unique Skills:
biotechnology
CAR-T Cell
CAR-T Therapy
cell & gene therapy
cell expansion
cell manufacturing
+16
|
2
Total Companies—
Oldest Founded1
Countries34
Unique SkillsSimilar Companies
Other organizations in the same industry
Servier India Private Limited
Pharmaceutical-ManufacturingTogether we are committed to therapeutic progress to serve patient needs.
Servier Indonesia
Pharmaceutical-ManufacturingCommitted to therapeutic progress to serve patient needs
Alternative Company Names
This company is also known as